Literature DB >> 15797691

New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder.

J R Calabrese1, D J Rapport, E A Youngstrom, K Jackson, S Bilali, R L Findling.   

Abstract

The rapid cycling variant of bipolar disorder is defined as the occurrence of four periods of either manic or depressive illness within 12 months. Patients suffering from this variant of bipolar disorder have an unmet need for effective treatment. This review examines two major studies in an attempt to update understanding of the current therapies available to treat rapid cycling patients. The first trial compares lamotrigine versus placebo in 182 patients studied for 6 months. The second is a recently completed, 20-month trial comparing divalproate and lithium in 60 patients. Both trials had a double-blind, randomized parallel-group design. The data from the latter study indicate that there are no large differences in efficacy between lithium and divalproate in the long-term treatment of rapid cycling bipolar disorder. In addition, lamotrigine has the potential to complement the spectrum of lithium and divalproate through its greater efficacy for depressive symptoms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15797691     DOI: 10.1016/j.eurpsy.2004.12.003

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  9 in total

1.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 2.  Mood-stabilizers target the brain arachidonic acid cascade.

Authors:  Jagadeesh S Rao; Stanley I Rapoport
Journal:  Curr Mol Pharmacol       Date:  2009-06       Impact factor: 3.339

Review 3.  Rapid cycling bipolar disorder: clinical characteristics and treatment options.

Authors:  William Coryell
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex.

Authors:  Yunyoung C Chang; Stanley I Rapoport; Jagadeesh S Rao
Journal:  Neurochem Res       Date:  2008-08-22       Impact factor: 3.996

5.  Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex.

Authors:  Ho-Joo Lee; Renee N Ertley; Stanley I Rapoport; Richard P Bazinet; Jagadeesh S Rao
Journal:  Neurochem Res       Date:  2007-12-14       Impact factor: 3.996

6.  Lamotrigine and Lithium Combination for Treatment of Rapid Cycling Bipolar Disorder: Results From Meta-Analysis.

Authors:  Gao Zhihan; Sun Fengli; Lv Wangqiang; Shen Dong; Jin Weidong
Journal:  Front Psychiatry       Date:  2022-07-14       Impact factor: 5.435

7.  A critical review of the recent literature and selected therapy guidelines since 2006 on the use of lamotrigine in bipolar disorder.

Authors:  Anja Tränkner; Christian Sander; Peter Schönknecht
Journal:  Neuropsychiatr Dis Treat       Date:  2013-01-18       Impact factor: 2.570

8.  Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder.

Authors:  Ho-Joo Lee; Jagadeesh S Rao; Lisa Chang; Stanley I Rapoport; Richard P Bazinet
Journal:  Psychopharmacology (Berl)       Date:  2007-05-09       Impact factor: 4.415

9.  Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study.

Authors:  D J Muzina; C Momah; J M Eudicone; A Pikalov; R D McQuade; R N Marcus; R Sanchez; B X Carlson
Journal:  Int J Clin Pract       Date:  2008-03-25       Impact factor: 2.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.